Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 20/20 | 1.00 |
| ▸ | GABRB3 | P28472 | 20/20 | 1.00 |
| ▸ | GABRA3 | P34903 | 20/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 2/20 | 1.00 |
| ▸ | GABRA5 | P31644 | 1/20 | 1.00 |
| ▸ | GABRA2 | P47869 | 1/20 | 1.00 |
| ▸ | GABRA4 | P48169 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15203206 | 0.91 | GABRG2 (0.84) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL17364047 | 0.90 | GABRG2 (0.82) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7663082 | 0.87 | GABRG2 (0.77) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL15386010 | 0.86 | GABRG2 (0.75) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL17368154 | 0.84 | GABRG2 (0.73) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7671983 | 0.82 | GABRG2 (0.70) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7667383 | 0.81 | GABRG2 (0.69) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7665235 | 0.81 | GABRG2 (0.70) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL13641706 | 0.81 | GABRG2 (0.69) | GABRG2GABRB3GABRA3GABRA1GABRA5 | |
| SCHEMBL7672131 | 0.81 | GABRG2 (0.68) | GABRG2GABRB3GABRA3GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | claimed |
| WO-2024229174-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2024-11-07 | — | — | WO | claimed |
| CN-118786209-A | Method for differentiating hematopoietic stem/progenitor cells into NK cells | 苏州血霁生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | BEXSON BIOMEDICAL, INC. | 2023-12-21 | — | — | US | claimed |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2022-12-15 | — | — | US | claimed |
| US-11083732-B2 | Use of negative modulators of GABA receptors containing alpha5 subunits as fast acting antidepressants | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2021-08-10 | — | — | US | claimed |
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-06-25 | — | — | US | claimed |
| US-6355638-B1 | COGNITION ACTIVATORS | MERCK SHARP & DOHME LTD. (GB) | 2002-03-12 | — | — | US | claimed |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | RICHTER GEDEON NYRT. (HU) | 2026-05-26 | — | — | US | disclosed |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4126858-B1 | DIHYDRO-2-PYRROLO[3,4-C]PYRIDINE DERIVATIVES AS GABAA A5 RECEPTOR MODULATORS | RICHTER GEDEON NYRT (HU) | 2026-03-18 | — | — | EP | disclosed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260033761-A1 | CHARACTERISATION OF NEUROLOGICAL DYSFUNCTION | HOFFMANN LA ROCHE (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2011153377-A2 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-12-08 | — | — | WO | disclosed |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | disclosed |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | disclosed |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-09-15 | — | — | US | disclosed |
| US-20070299096-A1 | Treating Learning Deficits With Inhibitors of Hmg CoA Reductase | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2007-12-27 | — | — | US | disclosed |
| US-6355638-B1 | COGNITION ACTIVATORS | MERCK SHARP & DOHME LTD. (GB) | 2002-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200199119-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | GABRG2 15/4885GABRB3 13/4885GABRA3 4/4885 |
| US-20260033761-A1 | CHARACTERISATION OF NEUROLOGICAL DYSFUNCTION | PMP22, PARK7, NCS1 | GABRG2 425/4885GABRB3 331/4885GABRA3 142/4885 |
| US-20230405018-A1 | FLUMAZENIL FORMULATIONS FOR SUBCUTANEOUS INJECTION AND METHODS OF TREATMENT USING GABA RECEPTOR MODULATORS | GABBR1, GABBR2, GABRB2 | GABRG2 14/4885GABRB3 9/4885GABRA3 12/4885 |
| US-12637468-B2 | Substituted [1,2,4]triazolo[4,3-b]pyridazines as GABAA receptor modulators | GABRA6, GABRA1, GABRB1 | GABRG2 17/4885GABRB3 12/4885GABRA3 8/4885 |
| US-20110224278-A1 | METHODS AND COMPOSITIONS FOR TREATING A SUBJECT FOR CENTRAL NERVOUS SYSTEM (CNS) INJURY | GABBR2, GABBR1, GABRR3 | GABRG2 13/4885GABRB3 8/4885GABRA3 7/4885 |
| US-12637455-B2 | Naphthyridine and pyrido[3,4-c]pyridazine derivatives as GABAA α5 receptor modulators | GABRA5, GABRA1, GABRB1 | GABRG2 15/4885GABRB3 6/4885GABRA3 5/4885 |
| US-20220396572-A1 | Deuterated Alpha5 subunit-selective Negative Allosteric Modulators of Gamma-Aminobutyric Acid Type A Receptors as Fast Acting Treatment for Depression and Mood Disorders | GABRA5, GABRA4, GABRA1 | GABRG2 15/4885GABRB3 13/4885GABRA3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.